Biased signalling and proteinase‐activated receptors (PAR s): targeting inflammatory disease
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Although it has been known since the 1960s that trypsin and chymotrypsin can mimic hormone action in tissues, it took until the 1990s to discover that serine proteinases can regulate cells by cleaving and activating a unique four‐member family of GPCR s known as proteinase‐activated receptors (PAR s).PAR activation involves the proteolytic exposure of its N‐terminal receptor sequence that folds back to function as a ‘tethered’ receptor‐activating ligand (TL). A key N‐terminal arginine in each of PARs 1 to 4 has been singled out as a target for cleavage by thrombin (PARs 1, 3 and 4), trypsin (PARs 2 and 4) or other proteases to unmask the TL that activates signalling via G q, Gior G 12/13. Similarly, synthetic receptor‐activating peptides, corresponding to the exposed ‘TL sequences’ (e.g.SFLLRN—, for PAR1 or SLIGRL— for PAR2) can, like proteinase activation, also drive signalling via G q,G iand G 12/13, without requiring receptor cleavage. Recent data show, however, that distinct proteinase‐revealed ‘non‐canonical’PAR tethered‐ligand sequences and PAR‐activating agonist and antagonist peptide analogues can induce ‘biased’PAR signalling, for example, via G 12/13‐MAPK inase instead of G q‐calcium. This overview summarizes implications of this ‘biased’ signalling by PAR agonists and antagonists for the recognized roles the PAR s play in inflammatory settings. Linked Articles: This article is part of a themed section on Molecular Pharmacology of GPCRs. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2014.171.issue‐5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dulon, S., Leduc, D., Cottrell, G. S., D'Alayer, J., Hansen, K. K., Bunnett, N. W., Hollenberg, M. D., Pidard, D., & Chignard, M. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0274oc · Cited by 139 · cited 3×
“For instance, thrombin activates PARs 1 and 4, but not PAR2; trypsin at low concentrations can activate PAR2 and PAR4, but disarms PAR1 (Kawabata et al., 1999); and Pseudomonas elastase disarms trypsin-mediated activation of PAR2 (Dulon et al., 2005).”
BackgroundSelf-citation
Cited by
Advances in therapeutic peptides targeting G protein-coupled receptors
Davenport, A. P., Scully, C. C. G., de Graaf, C., Brown, A. J. H., & Maguire, J. J. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0062-z · Cited by 275
Activated protein C: biased for translation
Griffin, J. H., Zlokovic, B. V., & Mosnier, L. O. (2015) · Blood · doi:10.1182/blood-2015-02-355974 · Cited by 257
“Elastase cleaves PAR1 at Leu45, and in vitro signaling effects differ somewhat from those of thrombin.(27,38) The in vivo importance and consequences of these alternative cleavages in PAR1 by other proteases are not yet as clear as are those for the actions of thrombin and APC.”
BackgroundCommunity guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232
Molecular mechanisms regulating Proteinase-Activated Receptors (PARs)
Chandrabalan, A., & Ramachandran, R. (2021) · The FEBS Journal · doi:10.1111/febs.15829 · Cited by 83
Self-citationNew insight into the agonism of protease-activated receptors as an immunotherapeutic strategy
Jiang, Y., & Lu, L. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105614 · Cited by 7
Metadata
- Authors
- Hollenberg, M. D., Mihara, K., Polley, D., Suen, J. Y., Han, A., Fairlie, D. P., & Ramachandran, R.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2014-02-27
- Volume
- 171
- Issue
- 5
- Pages
- 1180-1194
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W1827703464
- Cited by
- 176
- References
- 1
- FWCI
- 10.88
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.